Publications for Ian Davis
Publications for Ian Davis
2013
Grimison, P., Houghton, B., Chatfield, M.,
Toner, G., Davis, I., Martin, J., Hovey, E.,
Stockler, M. (2013). Patterns of management and
surveillance imaging amongst medical
oncologists in Australia for stage I testicular
cancer. BJU International, 112(2), E35-E43. <a
href="http://dx.doi.org/10.1111/bju.12221">[Mo
re Information]</a>
Olver, I., Grimison, P., Chatfield, M., Stockler,
M., Toner, G., Gebski, V., Harrup, R., Underhill,
C., Kichenadasse, G., Singhal, N., Boland, A.,
McDonald, A., et al (2013). Results of a 7-day
aprepitant schedule for the prevention of nausea
and vomiting in 5-day cisplatin-based germ cell
tumor chemotherapy. Supportive Care in
Cancer, 21(6), 1561-1568. <a
href="http://dx.doi.org/10.1007/s00520-012-169
6-0">[More Information]</a>
2011
Svobodova, S., Browning, J., MacGregor, D.,
Pollara, G., Scolyer, R., Murali, R., Thompson,
J., Deb, S., Azad, A., Davis, I., et al (2011).
Cancer-testis antigen expression in primary
cutaneous melanoma has independent prognostic
value comparable to that of Breslow thickness,
ulceration and mitotic rate. European Journal of
Cancer, 47(3), 460-469. <a
href="http://dx.doi.org/10.1016/j.ejca.2010.09.04
2">[More Information]</a>
Lawrentschuk, N., Lee, F., Jones, G.,
Rigopoulos, A., Mountain, A., O'Keefe, G.,
Papenfuss, A., Bolton, D., Davis, I., Scott, A.
(2011). Investigation of hypoxia and carbonic
anhydrase IX expression in a renal cell
carcinoma xenograft model with oxygen tension
measurements and (124)I-cG250 PET/CT.
Urologic Oncology: Seminars and Original
Investigations, 29(4), 411-420. <a
href="http://dx.doi.org/10.1016/j.urolonc.2009.0
3.028">[More Information]</a>
2009
CD133+ melanoma cells. Cancer Immunology,
Immunotherapy: other biological response
modifications, 58(10), 1635-1646. <a
href="http://dx.doi.org/10.1007/s00262-009-067
2-0">[More Information]</a>
Klein, O., Ebert, L., Nicholaou, T., Browning, J.,
Russell, S., Zuber, M., Jackson, H., Dimopoulos,
N., Tan, B., Hoos, A., Davis, I., et al (2009).
Melan-A-specific cytotoxic T cells are associated
with tumor regression and autoimmunity
following treatment with anti-CTLA-4. Clinical
Cancer Research, 15(7), 2507-2513. <a
href="http://dx.doi.org/10.1158/1078-0432.CCR08-2424">[More Information]</a>
Nicholaou, T., Ebert, L., Davis, I., McArthur, G.,
Jackson, H., Dimopoulos, N., Tan, B.,
Maraskovsky, E., Miloradovic, L., Hopkins, W.,
et al (2009). Regulatory T-cell-mediated
attenuation of T-cell responses to the NY-ESO-1
ISCOMATRIX vaccine in patients with
advanced malignant melanoma. Clinical Cancer
Research. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=19276262">[More Information]</a>
Kelly, M., Lee, S., Lee, F., Smyth, F., Davis, I.,
Brechbiel, M., Scott, A. (2009). Therapeutic
efficacy of 177Lu-CHX-A''-DTPA-hu3S193
radioimmunotherapy in prostate cancer is
enhanced by EGFR inhibition or docetaxel
chemotherapy. The Prostate, 69(1), 92-104. <a
href="http://dx.doi.org/10.1002/pros.20856">[M
ore Information]</a>
2008
Davis, I. (2008). Advances in the treatment of
castrate-resistant prostate cancer. Asia Pacific
Journal of Oncology and Hematology, 1, 52-55.
Davis, I., Desai, J. (2008). Clinical use of
therapies targeting tumor vasculature and stroma.
Current Cancer Drug Targets, 8(6), 498-508. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=18781896">[More Information]</a>
Ebert, L., Liu, Y., Clements, C., Robson, N.,
Jackson, H., Markby, J., Dimopoulos, N., Tan,
B., Luescher, I., Davis, I., et al (2009). A long,
naturally presented immunodominant epitope
from NY-ESO-1 tumor antigen: implications for
cancer vaccine design. Cancer Research, 69(3),
1046-1054. <a
href="http://dx.doi.org/10.1158/0008-5472.CAN
-08-2926">[More Information]</a>
John, T., Caballero, O., Svobodová, S., Kong,
A., Chua, R., Browning, J., Fortunato, S., Deb,
S., Hsu, M., Hsu, M., Davis, I., et al (2008).
ECSA/DPPA2 is an embryo-cancer antigen that
is coexpressed with cancer-testis antigens in
non-small cell lung cancer. Clinical Cancer
Research, 14(11), 3291-3298. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=18519755">[More Information]</a>
Gedye, C., Quirk, J., Browning, J., Svobodová,
S., John, T., Sluka, P., Dunbar, P., Corbeil, D.,
Cebon, J., Davis, I. (2009). Cancer/testis antigens
can be immunological targets in clonogenic
Frederiksen, K., Lundsgaard, D., Freeman, J.,
Hughes, S., Holm, T., Skrumsager, B., Petri, A.,
Hansen, L., McArthur, G., Davis, I., et al (2008).
IL-21 induces in vivo immune activation of NK
Publications for Ian Davis
cells and CD8(+) T cells in patients with
metastatic melanoma and renal cell carcinoma.
Cancer Immunology, Immunotherapy: other
biological response modifications, 57(10),
1439-1449. <a
href="http://dx.doi.org/10.1007/s00262-008-047
9-4">[More Information]</a>
Lawrentschuk, N., Appu, S., Chao, I., Chan, Y.,
Rogerson, J., Davis, I. (2008). Peripheral
primitive neuroectodermal tumor arising from
the seminal vesicle. Urologia Internationalis,
80(2), 212-215. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=18362495">[More Information]</a>
John, T., Black, M., Toro, T., Leader, D., Gedye,
C., Davis, I., Guilford, P., Cebon, J. (2008).
Predicting clinical outcome through molecular
profiling in stage III melanoma. Clinical Cancer
Research, 14(16), 5173-5180. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=18698035">[More Information]</a>
Pook, D., Davis, I. (2008). Targeted therapies in
renal cell carcinoma. Cancer Forum, 32,
155-158.
Pezaro, C., Davis, I. (2008). Targeted therapies
in the treatment of renal cell carcinoma. Current
Medicinal Chemistry, 15(12), 1166-1174. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=18473811">[More Information]</a>
Ebert, L., Bee, S., Browning, J., Svobodova, S.,
Russell, S., Kirkpatrick, N., Gedye, C., Moss, D.,
Ng, S., MacGregor, D., Davis, I., et al (2008).
The Regulatory T Cell–Associated Transcription
Factor FoxP3 Is Expressed by Tumor Cells.
Cancer Research, 68(8), 3001-2009. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=18413770">[More Information]</a>
Grossmann, M., Premaratne, E., Desai, J., Davis,
I. (2008). Thyrotoxicosis during sunitinib
treatment for renal cell carcinoma. Clinical
Endocrinology, 69(4), 669-672. <a
href="http://dx.doi.org/10.1111/j.1365-2265.200
8.03253.x">[More Information]</a>
2007
Scott, A., Tebbutt, N., Lee, F., Cavicchiolo, T.,
Liu, Z., Gill, S., Poon, A., Hopkins, W., Smyth,
F., Davis, I., et al (2007). A phase I
biodistribution and pharmacokinetic trial of
humanized monoclonal antibody Hu3s193 in
patients with advanced epithelial cancers that
express the Lewis-Y antigen. Clinical Cancer
Research, 13(11), 3286-3292. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17545534">[More Information]</a>
Davis, I., Wiseman, G., Lee, F., Gansen, D.,
Hopkins, W., Papenfuss, A., Liu, Z., Moynihan,
T., Croghan, G., Adjei, A., et al (2007). A phase
I multiple dose, dose escalation study of cG250
monoclonal antibody in patients with advanced
renal cell carcinoma. Cancer Immunity, 7, 131-13 - 8. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17705349">[More Information]</a>
Davis, I., Liu, Z., Saunders, W., Lee, F.,
Spirkoska, V., Hopkins, W., Smyth, F., Chong,
G., Papenfuss, A., Chappell, B., et al (2007). A
pilot study of monoclonal antibody cG250 and
low dose subcutaneous IL-2 in patients with
advanced renal cell carcinoma. Cancer
Immunity, 7(August), 14-1-14-9. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17705350">[More Information]</a>
Davis, I., Skrumsager, B., Cebon, J., Nicholaou,
T., Barlow, J., Moller, N., Skak, K., Lundsgaard,
D., Frederiksen, K., Thygesen, P., et al (2007).
An open-label, two-arm, phase I trial of
recombinant human interleukin-21 in patients
with metastatic melanoma. Clinical Cancer
Research, 13(12), 3630-3636. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17575227">[More Information]</a>
Lawrentschuk, N., Davis, I., Bolton, D., Scott, A.
(2007). Diagnostic and therapeutic use of
radioisotopes for bony disease in prostate cancer:
current practice. International Journal of
Urology, 14(2), 89-95. <a
href="http://dx.doi.org/10.1111/j.1442-2042.200
6.01659.x">[More Information]</a>
Chew, S., Wood, B., Canaan, C., Browning, J.,
MacGregor, D., Davis, I., Cebon, J., Tait, B.,
McNaughton, D. (2007). Fourier transform
infrared imaging as a method for detection of
HLA class I expression in melanoma without the
use of antibody. Tissue Antigens: immune
response genetics, 69(Supplement 1), 252-258.
<a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17445214">[More Information]</a>
Cebon, J., Gedye, C., John, T., Davis, I. (2007).
Immunotherapy of advanced or metastatic
melanoma. Clinical advances in hematology &
oncology, 5(12), 994-1006. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=18277962">[More Information]</a>
Davis, I., Skak, K., Smyth, M., Kristjansen, P.,
Publications for Ian Davis
Miller, D., Sivakumar, P. (2007). Interleukin-21
signaling: functions in cancer and autoimmunity.
Clinical Cancer Research, 13(23), 6926-6932.
<a
href="http://dx.doi.org/10.1158/1078-0432.CCR07-1238">[More Information]</a>
Davis, I., Toner, G., Broad, A., Campano, L.,
Rosenthal, M. (2007). Phase II trial of
anti-idiotypic p53 peptides (Pentrys) plus
granulocyte-macrophage colony-stimulating
factor in patients with hormone-refractory
prostate cancer. Asia-Pacific Journal of Clinical
Oncology, 3(3), 148-155.
Lawrentschuk, N., Bolton, D., Davis, I., Scott, A.
(2007). Renal cell cancer and positron emission
tomography - an evolving diagnostic and
therapeutic relationship. Current Medical
Imaging Reviews, 3, 17-26.
Desai, J., Gurney, H., Pavlakis, N., McArthur,
G., Davis, I. (2007). Sunitinib malate in the
treatment of renal cell carcinoma and
gastrointestinal stromal tumor:
Recommendations for patient management.
Asia-Pacific Journal of Clinical Oncology, 3(4),
167-176. <a
href="http://dx.doi.org/10.1111/j.1743-7563.200
7.00136.x">[More Information]</a>
Research, 16(4), 347-355. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16845331">[More Information]</a>
Nicholaou, T., Ebert, L., Davis, I., Robson, N.,
Klein, O., Maraskovsky, E., Chen, W., Cebon, J.
(2006). Directions in the immune targeting of
cancer: lessons learned from the cancer-testis Ag
NY-ESO-1. Immunology and Cell Biology,
84(3), 303-317. <a
href="http://dx.doi.org/10.1111/j.1440-1711.200
6.01446.x">[More Information]</a>
Goldstein, D., Ackland, S., Bell, D., Olver, I.,
Davis, I., Rosenthal, M., Toner, G., Pinel, M.,
Byrne, M. (2006). Phase II study of vinflunine in
patients with metastatic renal cell carcinoma.
Investigational New Drugs, 24(5), 429-434. <a
href="http://dx.doi.org/10.1007/s10637-006-643
7-0">[More Information]</a>
Lawrentschuk, N., Davis, I., Bolton, D., Scott, A.
(2006). Positron emission tomography (PET),
immuno-PET and radioimmunotherapy in renal
cell carcinoma: a developing diagnostic and
therapeutic relationship. BJU International,
97(5), 916-922. <a
href="http://dx.doi.org/10.1111/j.1464-410X.200
6.06125.x">[More Information]</a>
Nicholaou, T., Wong, R., Davis, I. (2007).
Tumour lysis syndrome in a patient with
renal-cell carcinoma treated with sunitinib
malate. The Lancet, 369(9577), 1923-1924. <a
href="http://dx.doi.org/10.1016/S0140-6736(07)
60903-9">[More Information]</a>
Lawrentschuk, N., Davis, I., Bolton, D., Scott, A.
(2006). Positron emission tomography and
molecular imaging of the prostate: an update.
BJU International, 97(5), 923-931. <a
href="http://dx.doi.org/10.1111/j.1464-410X.200
6.06040.x">[More Information]</a>
2006
Jackson, H., Dimopoulos, N., Mifsud, N., Tai,
T., Chen, Q., Svobodova, S., Browning, J.,
Luescher, I., Stockert, E., Old, L., Davis, I., et al
(2006). Striking immunodominance hierarchy of
naturally occurring CD8+ and CD4+ T cell
responses to tumor antigen NY-ESO-1. The
Journal of Immunology, 176(10), 5908-5917. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16670298">[More Information]</a>
Gan, H., Mitchell, P., Galettis, P., Davis, I.,
Cebon, J., De Souza, P., Links, M. (2006). A
phase 1 and pharmacokinetic study of
gemcitabine and oxaliplatin in patients with solid
tumors. Cancer Chemotherapy and
Pharmacology, 58(2), 157-164. <a
href="http://dx.doi.org/10.1007/s00280-005-015
2-y">[More Information]</a>
Davis, I., Chen, Q., Morris, L., Quirk, J., Stanley,
M., Tavarnesi, M., Parente, P., Cavicchiolo, T.,
Hopkins, W., Jackson, H., et al (2006). Blood
dendritic cells generated with Flt3 ligand and
CD40 ligand prime CD8+ T cells efficiently in
cancer patients. Journal of Immunotherapy,
29(5), 499-511. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16971806">[More Information]</a>
Lim, E., Browning, J., MacGregor, D., Davis, I.,
Cebon, J. (2006). Desmoplastic melanoma:
comparison of expression of differentiation
antigens and cancer testis antigens. Melanoma
Barrow, C., Browning, J., MacGregor, D., Davis,
I., Sturrock, S., Jungbluth, A., Cebon, J. (2006).
Tumor antigen expression in melanoma varies
according to antigen and stage. Clinical Cancer
Research, 12(3), 764-771. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16467087">[More Information]</a>
Lawrentschuk, N., Rigopoulos, A., Lee, F.,
Davis, I., Scott, A., Bolton, D. (2006).
Xenografting tumour beneath the renal capsule
using modern surgical equipment. European
Surgical Research, 38(3), 340-346. <a
href="http://dx.doi.org/10.1159/000094093">[M
ore Information]</a>
Publications for Ian Davis
2005
Davis, I., Kiers, L., MacGregor, L., Quinn, M.,
Arezzo, J., Green, M., Rosenthal, M., Chia, M.,
Michael, M., Bartley, P., et al (2005). A
randomized, double-blinded, placebo-controlled
phase II trial of recombinant human leukemia
inhibitory factor (rhuLIF, emfilermin, AM424)
to prevent chemotherapy-induced peripheral
neuropathy. Clinical Cancer Research, 11(5),
1890-1898. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15756015">[More Information]</a>
Lawewntschuk, N., Poon, A., Foo, S., Putra, L.,
Murone, C., Davis, I., Bolton, D., Scott, A.
(2005). Assessing regional hypoxia in human
renal tumours using 18F-fluoromisonidazole
positron emission tomography. BJU
International, 96(4), 540-546. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16104907">[More Information]</a>
John, T., Cebon, J., Davis, I. (2005).
Biochemotherapy for the treatment of metastatic
melanoma at the Austin Hospital. Asia-Pacific
Journal of Clinical Oncology, 1, 81-87.
Davis, I., Zeier, M. (2005). Can't cope with
'acopia'. Internal Medicine Journal, 35(9), 574;
author reply 574-5. <a
href="http://dx.doi.org/10.1111/j.1445-5994.200
5.00916.x">[More Information]</a>
Chen, Q., Jackson, H., Shackleton, M., Parente,
P., Hopkins, W., Sturrock, S., MacGregor, D.,
Maraskovsky, E., Tai, T., Dimopoulos, N.,
Davis, I., et al (2005). Characterization of
antigen-specific CD8+ T
lymphocyte responses in skin and peripheral
blood
following intradermal peptide vaccination.
Cancer Immunity, 5, 5-1-5-7. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15755075">[More Information]</a>
Scott, A., Liu, Z., Murone, C., Johns, T.,
MacGregor, D., Smyth, F., Lee, F., Cebon, J.,
Davis, I., Hopkins, W., et al (2005).
Immunological effects of chimeric anti-GD3
monoclonal antibody KM871 in patients with
metastatic melanoma. Cancer Immunity, 5,
3-1-3-12. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15723450">[More Information]</a>
Harris, M., Berlangieri, S., Cebon, J., Davis, I.,
Scott, A. (2005). Impact of
2-deoxy-2[F-18]fluoro-D-glucose Positron
Emission Tomography on the management of
patients with advanced melanoma. Molecular
Imaging and Biology, 7(4), 304-308. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16041590">[More Information]</a>
Chong, G., Lee, F., Hopkins, W., Tebbutt, N.,
Cebon, J., Mountain, A., Chappell, B.,
Papenfuss, A., Schleyer, P., Davis, I., et al
(2005). Phase I trial of 131I-huA33 in patients
with advanced colorectal carcinoma. Clinical
Cancer Research, 11(13), 4818-4826. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16000579">[More Information]</a>
Murphy, R., Green, S., Ritter, G., Cohen, L.,
Ryan, D., Woods, W., Rubira, M., Cebon, J.,
Davis, I., Sjolander, A., et al (2005).
Recombinant NY-ESO-1 cancer antigen:
production and purification under cGMP
conditions. Preparative Biochemistry and
Biotechnology, 35(2), 119-134. <a
href="http://dx.doi.org/10.1081/PB-200054732"
>[More Information]</a>
Schnurr, M., Chen, Q., Shin, A., Chen, W., Toy,
T., Jenderek, C., Green, S., Miloradovic, L.,
Drane, D., Davis, I., et al (2005). Tumor antigen
processing and presentation depend critically on
dendritic cell type and the mode of antigen
delivery. Blood, 105(6), 2465-2472. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15546948">[More Information]</a>
John, T., Davis, I. (2005). Ventricular metastasis
resulting in disseminated intravascular
coagulation. World Journal of Surgical
Oncology, 3(1), 29. <a
href="http://dx.doi.org/10.1186/1477-7819-3-29"
>[More Information]</a>
2004
Putra, L., Lawrentschuk, N., Ballok, Z., Hannah,
A., Poon, A., Tauro, A., Davis, I., Hicks, R.,
Bolton, D., Scott, A. (2004).
18F-fluorodeoxyglucose positron emission
tomography in evaluation of germ cell tumor
after
chemotherapy. International Journal of Urology,
64(6), 1202-1207. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15596197">[More Information]</a>
Mitchell, P., Basser, R., Chipman, M., Grigg, A.,
Mansfield, R., Cebon, J., Davis, I., Appia, F.,
Green, M. (2004). A phase II study of
escalated-dose docetaxel with granulocyte
colony-stimulating factor support in patients with
advanced breast cancer. Annals of Oncology,
15(4), 585-589. <a
Publications for Ian Davis
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15033663">[More Information]</a>
Jackson, H., Dimopoulos, N., Chen, Q., Luke, T.,
Tai, T., Maraskovsky, E., Old, L., Davis, I.,
Cebon, J., Chen, W. (2004). A robust human
T-cell culture method suitable for monitoring
CD8+ and CD4+ T-cell responses from cancer
clinical trial samples. Journal of Immunological
Methods, 291(1-2). <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15345304">[More Information]</a>
Chen, Q., Jackson, H., Parente, P., Luke, T.,
Rizkalla, M., Tai, T., Zhu, H., Mifsud, N.,
Dimopoulos, N., Masterman, K., Davis, I., et al
(2004). Immunodominant CD4+ responses
identified in a patient vaccinated with full-length
NY-ESO-1 formulated with ISCOMATRIX
adjuvant. Proceedings of the National Academy
of Sciences of the United States of America
(PNAS), 101(25), 9363-9368. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15197261">[More Information]</a>
Vaughan, H., Svobodova, S., MacGregor, D.,
Sturrock, S., Jungbluth, A., Browning, J., Davis,
I., Parente, P., Chen, Y., Stockert, E., et al
(2004). Immunohistochemical and molecular
analysis of human melanomas for expression of
the human cancer-testis antigens NY-ESO-1 and
LAGE-1. Clinical Cancer Research, 10(24),
8396-8404. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15623618">[More Information]</a>
Davis, I., Chen, W., Jackson, H., Parente, P.,
Shackleton, M., Hopkins, W., Chen, Q.,
Dimopoulos, N., Luke, T., Murphy, R., et al
(2004). Recombinant NY-ESO-1 protein with
ISCOMATRIX adjuvant induces broad
integrated antibody and CD4(+) and CD8(+) T
cell responses in humans. Proceedings of the
National Academy of Sciences of the United
States of America (PNAS), 101(29),
10697-10702. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15252201">[More Information]</a>
Schnurr, M., Toy, T., Shin, A., Hartmann, G.,
Rothenfusser, S., Soellner, J., Davis, I., Cebon,
J., Maraskovsky, E. (2004). Role of adenosine
receptors in regulating chemotaxis and cytokine
production of plasmacytoid dendritic cells.
Blood, 103(4), 1391-1397. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=14551144">[More Information]</a>
Shackleton, M., Davis, I., Hopkins, W., Jackson,
H., Dimopoulos, N., Tai, T., Chen, Q., Parente,
P., Jefford, M., Masterman, K., et al (2004). The
impact of imiquimod, a Toll-like receptor-7
ligand (TLR7L), on the immunogenicity of
melanoma peptide vaccination with adjuvant Flt3
ligand. Cancer Immunity, 4, 9-1-9 - 11. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15384929">[More Information]</a>
2003
Mitchell, P., Basser, R., Chipman, M., Grigg, A.,
Cebon, J., Davis, I., Zalcberg, J., Ng, S., Appia,
F., Green, M. (2003). A phase I dose-escalation
study of docetaxel with granulocyte
colony-stimulating factor support in patients with
solid tumours. Annals of Oncology, 14(5),
788-794. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=12702535">[More Information]</a>
Gunawardana, D., Basser, R., Davis, I., Cebon,
J., Mitchell, P., Underhill, C., Kilpatrick, T.,
Reardon, K., Green, M., Bardy, P., et al (2003).
A phase I study of recombinant human leukemia
inhibitory factor in patients with advanced
cancer. Clinical Cancer Research, 9(6),
2056-2065. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=12796368">[More Information]</a>
Jefford, M., Schnurr, M., Toy, T., Masterman,
K., Shin, A., Beecroft, T., Tai, T., Shortman, K.,
Shackleton, M., Davis, I., et al (2003).
Functional comparison of DCs generated in vivo
with Flt3 ligand or in vitro from blood
monocytes: differential regulation of function by
specific classes of physiologic stimuli. Blood,
102(5), 1753-1763. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=12738673">[More Information]</a>
Cebon, J., Jäger, E., Shackleton, M., Gibbs, P.,
Davis, I., Hopkins, W., Gibbs, S., Chen, Q.,
Karbach, J., Jackson, H., et al (2003). Two phase
I studies of low dose recombinant human IL-12
with Melan-A and influenza peptides in subjects
with advanced malignant melanoma. Cancer
Immunity, 3, 1-18. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=12862418">[More Information]</a>